"Cytochrome P-450 CYP2C9" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cytochrome P-450 subtype that has specificity for acidic XENOBIOTICS. It oxidizes a broad range of important clinical drugs that fall under the categories of NONSTEROIDAL ANTI-INFLAMMATORY AGENTS; HYPOGLYCEMIC AGENTS; ANTCOAGULANTS; and DIURETICS.
| Descriptor ID |
D065729
|
| MeSH Number(s) |
D08.244.453.491.500.500 D08.811.682.690.708.170.450.500.500 D12.776.422.220.453.491.500.500
|
| Concept/Terms |
Cytochrome P-450 CYP2C9- Cytochrome P-450 CYP2C9
- CYP2C9, Cytochrome P-450
- Cytochrome P 450 CYP2C9
- P-450 CYP2C9, Cytochrome
- Cytochrome P450 PB-1
- Cytochrome P450 PB 1
- P450 PB-1, Cytochrome
- PB-1, Cytochrome P450
- Cytochrome P450 MP-4
- Cytochrome P450 MP 4
- MP-4, Cytochrome P450
- P450 MP-4, Cytochrome
- Cytochrome P450 MP-8
- Cytochrome P450 MP 8
- MP-8, Cytochrome P450
- P450 MP-8, Cytochrome
- CYP2C9
- CYPIIC9
|
Below are MeSH descriptors whose meaning is more general than "Cytochrome P-450 CYP2C9".
Below are MeSH descriptors whose meaning is more specific than "Cytochrome P-450 CYP2C9".
This graph shows the total number of publications written about "Cytochrome P-450 CYP2C9" by people in this website by year, and whether "Cytochrome P-450 CYP2C9" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 0 | 1 | 1 |
| 2011 | 0 | 1 | 1 |
| 2012 | 0 | 1 | 1 |
| 2015 | 0 | 1 | 1 |
| 2016 | 2 | 0 | 2 |
| 2017 | 2 | 0 | 2 |
| 2018 | 1 | 8 | 9 |
| 2019 | 3 | 0 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Cytochrome P-450 CYP2C9" by people in Profiles.
-
Steroid hormone-related polymorphisms associate with the development of bone erosions in rheumatoid arthritis and help to predict disease progression: Results from the REPAIR consortium. Sci Rep. 2019 10 15; 9(1):14812.
-
Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y12 Receptor Inhibitor Treatment in Percutaneous Coronary Intervention. JACC Cardiovasc Interv. 2019 08 26; 12(16):1521-1537.
-
Mutations in CYP2C9 and/or VKORC1 haplotype are associated with higher bleeding complications in patients with Budd-Chiari syndrome on warfarin. Hepatol Int. 2019 Mar; 13(2):214-221.
-
Interaction between warfarin and cannabis. Basic Clin Pharmacol Toxicol. 2019 Jan; 124(1):28-31.
-
Frequencies of poor metabolizer alleles of 12 pharmacogenomic actionable genes in Punjabi Sikhs of Indian Origin. Sci Rep. 2018 10 24; 8(1):15742.
-
Polymorphisms at phase I-metabolizing enzyme and hormone receptor loci influence the response to anti-TNF therapy in rheumatoid arthritis patients. Pharmacogenomics J. 2019 02; 19(1):83-96.
-
An improved LC-MS/MS method for simultaneous evaluation of CYP2C9, CYP2C19, CYP2D6 and CYP3A4 activity. Bioanalysis. 2018 Oct 01; 10(19):1577-1590.
-
Genotype-guided warfarin dosing vs. conventional dosing strategies: a systematic review and meta-analysis of randomized controlled trials. Br J Clin Pharmacol. 2018 09; 84(9):1868-1882.
-
Pharmacogenetics of vitamin K antagonists and bleeding risk prediction in atrial fibrillation. Eur J Clin Invest. 2018 Jun; 48(6):e12929.
-
Effects of Ojeok-san on the Pharmacokinetics of Celecoxib at Steady-state in Healthy Volunteers. Basic Clin Pharmacol Toxicol. 2018 Jul; 123(1):51-57.